Century Therapeutics (NASDAQ:IPSC) Price Target Cut to $5.00 by Analysts at Guggenheim
Century Therapeutics (NASDAQ:IPSC – Free Report) had its target price decreased by Guggenheim from $12.00 to $5.00 in a research note published on Friday morning,Benzinga reports. Guggenheim currently has a buy rating on the stock. A number of other equities research analysts have also weighed in on IPSC. HC Wainwright reiterated a “buy” rating and […]
Century Therapeutics (NASDAQ:IPSC – Free Report) had its target price decreased by Guggenheim from $12.00 to $5.00 in a research note published on Friday morning,Benzinga reports. Guggenheim currently has a buy rating on the stock. A number of other equities research analysts have also weighed in on IPSC. HC Wainwright reiterated a “buy” rating and […]
